BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, December 18, 2024
Breaking News: Holiday special – 25% off BioWorld subscriptions
See today's BioWorld Science
Home
» Toleranzia’s TOL-2 for myasthenia gravis enters toxicology study
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Immune
Toleranzia’s TOL-2 for myasthenia gravis enters toxicology study
Sep. 26, 2023
No Comments
Toleranzia AB has begun a regulatory GLP-toxicology study of TOL-2, being developed for myasthenia gravis. Animals will receive daily doses of TOL-2 on multiple days to determine the safety and tolerability of TOL-2.
BioWorld Science
Immune
